GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
A Study to Measure the Sun Protection Factor (SPF) and Ultraviolet-A Protection Factor (UVAPF) of Four Developmental Sunscreen Formulations
Not Applicable
Completed
- Conditions
- Sunscreening Agents
- Interventions
- Other: GlycerinOther: NGBUV000D, (Expected SPF 30)Other: Sunscreen formulation S2Other: P3 Standard, (Expected SPF 16)Other: NGBUV000A, (Expected SPF 30)Other: NGBUV000C, (Expected SPF 30)Other: NGBUV000B, (Expected SPF 30)
- First Posted Date
- 2017-05-17
- Last Posted Date
- 2019-07-22
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 8
- Registration Number
- NCT03157583
- Locations
- 🇩🇪
GSK Investigational Site, Schenefeld, Schleswig-Holstein, Germany
To Investigate the Impact of a Nutritional Supplement on Bone Turnover Markers in Indian Healthy Premenopausal Women (25- 45 Years) After 6 Months of Intervention
Not Applicable
Completed
- Conditions
- Growth and Development
- Interventions
- Dietary Supplement: Fortified Beverage PowderDietary Supplement: Non fortified beverage Powder
- First Posted Date
- 2017-05-16
- Last Posted Date
- 2019-04-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 114
- Registration Number
- NCT03155269
- Locations
- 🇮🇳
GSK Investigational Site, Pune, India
Study of Subjects With Diabetic Foot Ulcer (DFU)
Completed
- Conditions
- Diabetic Foot
- First Posted Date
- 2017-05-15
- Last Posted Date
- 2018-08-27
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1
- Registration Number
- NCT03153007
- Locations
- 🇺🇸
GSK Investigational Site, Bethesda, Maryland, United States
The Extended Salford Lung Study ("Ex-SLS") Data Access Project
Recruiting
- Conditions
- Asthma
- First Posted Date
- 2017-05-15
- Last Posted Date
- 2022-09-02
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 3500
- Registration Number
- NCT03152669
- Locations
- 🇬🇧
GSK Investigational Site, Manchester, United Kingdom
A Phase 1, First Time in Human (FTIH) Study to Evaluate GSK3352589, a REarranged During Transfection (RET) Growth Factor Receptor Tyrosine Kinase Inhibitor, in Healthy Volunteers
Phase 1
Completed
- Conditions
- Irritable Bowel Syndrome
- Interventions
- Drug: GSK3352589Drug: Matching Placebo
- First Posted Date
- 2017-05-15
- Last Posted Date
- 2019-08-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 68
- Registration Number
- NCT03154086
- Locations
- 🇦🇺
GSK Investigational Site, Adelaide, South Australia, Australia
Occurrence of Potential Bacterial and Viral Pathogens in Stable Chronic Obstructive Pulmonary Disease and During Acute Exacerbations of the Disease, in Asia Pacific
Not Applicable
Completed
- Conditions
- Respiratory Disorders
- Interventions
- Other: Sputum and blood sampling
- First Posted Date
- 2017-05-12
- Last Posted Date
- 2021-06-14
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 197
- Registration Number
- NCT03151395
- Locations
- 🇨🇳
GSK Investigational Site, Taipei, Taiwan
Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy in Participants With Castrate-resistant Prostate Cancer
Phase 1
Terminated
- Conditions
- Solid Tumours
- Interventions
- First Posted Date
- 2017-05-11
- Last Posted Date
- 2022-08-10
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 73
- Registration Number
- NCT03150056
- Locations
- 🇬🇧
GSK Investigational Site, Glasgow, United Kingdom
Bioequivalence Study Between GR37547 500 Milligrams (mg) Tablet Versus Ciprofloxacin 500 mg Tablet Reference Product in Healthy Adult Subjects
Phase 1
Completed
- Conditions
- Infections, Bacterial
- Interventions
- Drug: GR37547 tabletDrug: Ciprofloxacin reference tablet
- First Posted Date
- 2017-05-11
- Last Posted Date
- 2018-12-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 26
- Registration Number
- NCT03150082
- Locations
- 🇿🇦
GSK Investigational Site, Bloemfontein,, South Africa
Cryobiopsy Study to Assess Drug Distribution in Subjects With Suspected Interstitial Lung Disease
Completed
- Conditions
- Lung Diseases, Interstitial
- Interventions
- Drug: Ipratropium BromideProcedure: Flexible Bronchoscopy/Biopsy
- First Posted Date
- 2017-05-02
- Last Posted Date
- 2019-01-29
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 8
- Registration Number
- NCT03136120
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Study of Danirixin in Japanese Healthy Elderly Male Subjects
Phase 1
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: GSK1325756HDrug: Placebo
- First Posted Date
- 2017-05-02
- Last Posted Date
- 2019-04-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 34
- Registration Number
- NCT03136380
- Locations
- 🇯🇵
GSK Investigational Site, Tokyo, Japan
© Copyright 2025. All Rights Reserved by MedPath